INTRODUCTION

The clinicopathological classification of vascular anomalies, which was first proposed by Mulliken and Glowacki in 1982 [1], has continued to be a basic standard. The classification of these anomalies into two broad categories—tumors and vascular malformations—was the basis of the 2018 classification proposed by the International Society for the Study of Vascular Anomalies (ISSVA). However, there are still many limitations of pathophysiological analyses on the basis of clinical and histological findings [2-4]. Since recent studies have identified many genes potentially linked to vascular anomalies, several pathophysiological analyses based on these genes have been conducted, and potential new treatments have also been proposed. Since the 1990s, the genetic basis for vascular anomalies has been elucidated, and as a result, mutations associated with numerous types of lesions have been reported over the past few years [3]. Recent developments in sequencing technologies have opened new horizons in terms of genomic studies, and research in this field is actively expanding [5]. This article presents an introduction to genetic testing for vascular anomalies and provides a brief summary of the etiology and genetics of vascular anomalies.

GENETIC TESTS FOR VASCULAR ANOMALIES

In the past few decades, remarkable and unexpected advances in genetic testing have been made. The completion of the Human Genome Project in 2003 was followed by a veritable flood of discoveries regarding the genetic basis of various diseases [6]. Even-
Recent advances in genetic testing and next-generation sequencing (NGS) have allowed for a more detailed understanding of the genetic basis of vascular anomalies. Mutations can be classified into germline mutations and somatic mutations. Germline mutations pass from the parent to the offspring through germ cells, and can therefore be found in almost every cell in an individual. Somatic mutations occur only in a subgroup of cells (excluding germ cells) in an individual. Therefore, these mutations are not transmitted to the next generation. Instead, they are only transmitted to the offspring of the affected cells, giving rise to somatic mosaicism, which plays a major role in the development of vascular lesions. Somatic mutations can cause disease, as exemplified by cancer, where cells acquire somatic mutations and develop into tumors.

Although familial inheritance has also been reported, most vascular anomalies are sporadic. Germline mutations can be tested using blood, buccal mucosal cells, or lesion tissue samples; however, somatic mutations can only be found in lesion tissue samples. NGS has proven to be a valuable tool for discovering somatic mutations.

**GENETICS OF VASCULAR ANOMALIES**

The causal genes of vascular anomalies known to date are well organized in the ISSVA classification of vascular anomalies (c2018 ISSVA, available from: issva.org/classification) [11].

**Vascular tumors**

Infantile hemangioma (IH) arises from the proliferation of endothelial cells (ECs). Two main proposals have been made regarding the origins of ECs in IH: embolic placental angioblasts, which share placental markers (glucose transporter protein 1 [GLUT1], Fcγ receptor II, Lewis Y antigen, and merosin), and endothelial progenitor cells (CD133+/CD34+ circulating progenitor cells and stem cells) [12,13]. Vascular endothelial growth factor (VEGF)-A signaling is associated with IH. In the ECs in IH, the formation of IH has been shown to be caused by changes in the VEGF-A signaling pathway that are related to missense mutations in the genes encoding VEGFR2 (KDR) and TEM8 (ANTXR1) [14,15].

**Congenital hemangioma**

There are three types of congenital hemangioma (CH) that appear fully formed at birth: non-involuting CH, partially involuting CH, and rapidly involuting CH [15,16]. They are all GLUT1-negative. It has been reported that there is a mutation at the glutamine 209 (Gln209) position in GNAQ or GNA11, and the Gln209 missense mutation is known to activate GTP-dependent signaling, which leads to the constitutive activation of MAPK and/or YAP signaling [17].

**Pyogenic granuloma**

Pyogenic granuloma (PG) may be isolated or associated with a capillary malformation (CM). It has been reported that PGs associated with CM (secondary PGs) show a somatic GNAQ mutation reflecting an origin from CM cells. Furthermore, BRAF
somatic mutations were found in eight of 10 secondary PGs and NRAS mutations in one of 10. However, isolated PGs were associated with BRAF (four of 25) or KRAS (one of 25) mutations [18]. A somatic activating GNA14 mutation has been reported in one case and a GNA11 mutation in two cases [19].

Kaposiform hemangioendothelioma
Kaposiform hemangioendothelioma (KHE) is usually present at birth and is typically diagnosed in infancy or early childhood. The incidence of the Kasabach-Merritt phenomenon has been estimated at 42% to 71% in KHE [20]. GNA14 mutations were found in one of three KHE specimens and one of four closely related tufted angiomas [19].

Vascular malformations
Capillary malformation
CM is the most common type of vascular malformation [21]. GNAQ mutations were found in 80%–90% of cases with a sporadic or syndromic (Sturge-Weber syndrome) etiology [22]. GNA11 mutations were identified in three of eight specimens with diffuse CM and overgrowth of an extremity [23]. The GNAQ mutations in CM primarily present in ECs [24]. Atypical CM may co-occur with arteriovenous malformation (AVM) in a single patient. This entity, which is referred to as CM-AVM, can be subdivided into CM-AVM1 and CM-AVM2. CM-AVM1 is inherited in an autosomal dominant pattern and is caused by a RASA1 mutation [25]. One-third of patients with CM-AVM1 have fast-flow lesions; in contrast, the risk of fast-flow malformations is lower in CM-AVM2, which is caused by a loss-of-function mutation in EPHB4 [26].

Lymphatic malformations
Lymphatic malformations (LMs) are sporadic slow-flow lesions that are composed of multiple cystic structures, which can be macroscopic, microscopic or combined [27]. PIK3CA mutations were found in 16 of 17 specimens. Mutations in the PIK3CA gene can enhance the ability of its protein product to bind to the cell membrane or activate its kinase, which results in activation of the AKT/mTOR signaling pathway [28,29]. Rapamycin (sirolimus), which is well known as an mTOR inhibitor, has shown good efficacy and a favorable safety profile when used in patients [10]. Primary lymphedema is a type of vascular malformation that can be hereditary. Several mutations (VEGFR3/FLT-4, FOXC2, SOX18, CCBE1, etc.) have been identified in patients with primary lymphedema [15].

Venous malformations
Venous malformations (VMs) are usually sporadic, but can be familial [30]. Cutanoeumocusal autosomal dominant VM was found to be caused by TIE2 mutations, which were found in 80 of 130 specimens of sporadic VMs. Activating somatic mutations of PIK3CA have also been identified in sporadic VMs that lacked TEK/TIE2 mutations [3,15,31]. Verrucous VMs associated with the MAP3K3 mutation are hyperkeratotic abnormalities that affect the skin of limbs [32]. Glomuvenous malformation (GVM) is an autosomal dominant disease in which several small lesions are caused by germline or somatic loss-of-function mutations in glomulin (GLMN) [33]. GVMs have reported as requiring somatic second-hit mutations to trigger disease onset; the first mutation is inherited in an autosomal dominant manner, while the second mutation is acquired. Blue rubber bleb nevus syndrome, which is a non-hereditary condition, presents as multifocal VMs. This syndrome is associated with TIE2 mutations [34]. Cerebral cavernous malformations (CCMs) are characterized by enlarged capillary cavities in the central nervous system. In 9% of CCM patients, cutaneous lesions are also found. CCMs, which are associated with mutations in CCM1/KRIT1, CCM2/malcavernin, and CCM3/PDCD10, can be sporadic or familial [5,35].

Arteriovenous malformations
AVMs are anomalous connections between arteries and veins through a nidus or fistula, bypassing high-resistance capillary beds [36]. AVMs occur sporadically, and are associated with a mutation in the MAP2K1 gene [37]. Inherited AVMs can occur in the context of other conditions, such as hereditary hemorrhagic telangiectasia (HHT), and combined diseases such as CM-VM (see CM) and Parkes Weber syndrome [10,15,24].

Hereditary hemorrhagic telangiectasia
HHT is an autosomal dominant vascular dysplasia that can cause epistaxis, mucocutaneous telangiectasias, and/or visceral AVMs. Ninety percent of HHT cases are associated with a loss-of-function mutation of one of three identified genes. HHT1 is associated with mutations in endoglin (ENG), a co-receptor for activin-like receptor; HHT2 with mutations in activin receptor-like kinase 1 (ACVRL1); and juvenile polyposis/HHT syndrome with mutations in MADH4, which encodes the downstream effector SMAD4. HHT is associated with germline mutations in genes involved in the TGF-β/BMP signaling pathway [5,38,39].

Vascular malformations associated with other anomalies
Vascular malformations are one of the major components in various syndromes that cause enlargement of soft tissues or bones. Klippel-Trenaunay syndrome (KTS) presents with a
classic triad of port-wine stains, asymmetric extremity overgrowth, and underlying VMs or LMs [40,41]. In 19 of 21 KTS patients, PIK3CA mutations were found to play a role in the pathogenesis of the condition [42]. Macrocephaly-CM usually causes neurological abnormalities, and patients typically have CM on the upper lip, back, and/or limbs. These patients also have PIK3CA mutations [43]. CLOVES syndrome is characterized by congenital lipomatosis, overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies. Mutations in PIK3CA were identified in 36 of 38 patients [44]. Proteus syndrome, which features asymmetric growth of skeletal and connective tissue, cerebromedley nevi of the hands or feet, epidermal nevi, and underlying vascular malformations, results from a somatic activating mutation in AKT1 [45]. Maffucci syndrome features several enchondromas and soft-tissue VMs. This condition results from somatic mutations of isocitrate dehydrogenase (IDH), with 98% of cases caused by IDH1 mutations and 2% by IDH2 mutations [46].

**ABNORMAL SIGNALING PATHWAYS IN VASCULAR ANOMALIES**

These genetic mutations directly change the activities of intracellular signaling pathways, thereby influencing various downstream actions. The pathways most involved in vascular anomalies are the PI3K/AKT/mTOR and RAS/MAPK signaling pathways. Another important signaling mechanism is the TGF-β/SMAD signaling pathway, which plays a role in HHT (Fig. 1).

---

**Fig. 1. Mutations and signaling pathways in vascular anomalies**

Mutations in vascular abnormalities affect genes involved in tyrosine kinase signaling via the RAS or PIK3CA pathways. This figure is a schematic diagram of key genetic mutations related to signal transduction and vascular malformations in endothelial cells. Proteins mutated in other vascular disorders are indicated. Mutations in GNAQ/GNA11/GNA14, RASA1, and KRIT lead to constitutive activation of RAS/RAF/MEK/ERK signaling. Mutations in TIE2/TEK lead to permanent activation of the PIK3CA/AKT/mTOR pathway. AVM, arteriovenous malformation; BAVM, brain arteriovenous malformation; CCM, cerebral cavernous malformation; CM, capillary malformation; LCMCNPLOG, limb capillary malformation with congenital nonprogressive limb overgrowth; MD, Milroy’s disease; MCM, megalencephaly capillary malformation; NSCM, non-syndromic capillary malformation; PL, primary lymphedema; PWS, Parkes Weber syndrome; PWSWM, port wine stain with macrocheilia; SVAM, spinal arteriovenous malformation; SWS, Surge-Weber syndrome; TA, tufted angioma; VM, venous malformation; WMD, verrucous venous malformation.
CONCLUSIONS

Advances in DNA sequencing have yielded extensive knowledge regarding the etiological molecular mechanisms involved in the development of vascular anomalies. NGS is a very effective method of analyzing germline and somatic mutations of vascular anomalies, which have various phenotypes, and their associated dysfunctions. An important point to be emphasized is that somatic mutations and their mechanisms for vascular anomalies, which mainly are sporadic and unifocal, should be further studied in the future. Although many downstream effects remain unknown, it is clear that normalization of the affected signaling pathways is an important target for treatment. Mutation-specific targeted therapies are also being studied, which may result in a paradigm shift in therapeutic approaches to vascular anomalies. Further research into the cellular effects of mutations is expected to yield insights into the underlying pathophysiology that will enable new therapies to be developed.

NOTES

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Author contribution
Conceptualization: JS Kim, SK Hwang, HY Chung. Data curation: JS Kim, SK Hwang, HY Chung. Formal analysis: HY Chung. Funding acquisition: HY Chung. Methodology: HY Chung. Project administration: HY Chung. Visualization: JS Kim, HY Chung. Writing - original draft: JS Kim, HY Chung. Writing - review & editing: JS Kim, SK Hwang, HY Chung.

ORCID
Jong Seong Kim https://orcid.org/0000-0002-4725-9277
Su-Kyeong Hwang https://orcid.org/0000-0001-8294-7094
Ho Yun Chung https://orcid.org/0000-0001-7359-3044

REFERENCES
1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982;69:412-22.
2. Mulliken JB, Burrows PE, Fishman DJ. Mulliken and Young’s vascular anomalies: hemangiomas and malformations. 2nd ed. New York: Oxford University Press; 2013.
3. Greene AK, Goss JA. Vascular anomalies: from a clinicohisto-
logic to a genetic framework. Plast Reconstr Surg 2018;141:709e-717e.
4. Lee JW, Chung HY. Vascular anomalies of the head and neck: current overview. Arch Craniofac Surg 2018;19:243-7.
5. Queisser A, Boon LM, Vikkula M. Etiology and genetics of congenital vascular lesions. Otolaryngol Clin North Am 2018;51:41-53.
6. Collins PS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science 2003;300:286-90.
7. Sohn J. Next generation sequencing and anti-cancer therapy. J Korean Med Assoc 2019;62:119-29.
8. Koboldt DC, Steinberg KM, Larson DE, et al. The next-generation sequencing revolution and its impact on genomics. Cell 2013;155:27-38.
9. Wetzel-Strong SE, Detter MR, Marchuk DA. The pathobiology of vascular malformations: insights from human and model organism genetics. J Pathol 2017;241:281-93.
10. Adams DM. Practical genetic and biologic therapeutic considerations in vascular anomalies. Tech Vasc Interv Radiol 2019;22:100629.
11. International Society for the Study of Vascular Anomalies (ISSVA). ISSVA classification of vascular anomalies [Internet]. Milwaukee, WI: ISSVA; c2018 [cited 2020 May 11]. Available from: issva.org/classification.
12. North PE, Waner M, Brodsky MC. Are infantile hemangiomas of placental origin? Ophthalmology 2002;109:633-4.
13. Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. Version 2. J Clin Invest 2008;118:2592-9.
14. Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008;14:1236-46.
15. Uebelhoer M, Boon LM, Vikkula M. Vascular anomalies: from genetics toward models for therapeutic trials. Cold Spring Harb Perspect Med 2012;2:a009688.
16. Nasseri E, Piram M, McCuaig CC, et al. Partially involving congenital hemangiomas: a report of 8 cases and review of the literature. J Am Acad Dermatol 2014;70:75-9.
17. Ayturk UM, Couto JA, Hann S, et al. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. Am J Hum Genet 2016;98:789-95.
18. Grosseker L, Peterhof E, Evert M, et al. BRAF and RAS mutations in sporadic and secondary pyogenic granuloma. J Invest Dermatol 2016;136:481-6.
19. Lim YH, Bacchiorichi A, Qiu J, et al. GNA14 somatic mutation causes congenital and sporadic vascular tumors by...
MAPK activation. Am J Hum Genet 2016;99:443-50.
20. Ji Y, Chen S, Yang K, et al. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis 2020;15:39.
21. Lee JW, Chung HY. Capillary malformations (Portwine Stains) of the head and neck: natural history, investigations, laser, and surgical management. Otolaryngol Clin North Am 2018;51:197-211.
22. Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013;368:1971-9.
23. Couto JA, Ayturk UM, Konczyk DJ, et al. A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis 2017;20:303-6.
24. Couto JA, Huang L, Vivero MP, et al. Endothelial cells from capillary malformations are enriched for somatic GNAQ mutations. Plast Reconstr Surg 2016;137:77e-82e.
25. Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003;73:1240-9.
26. Amyere M, Revencu N, Helaers R, et al. Germline loss-of-function mutations in EPHB4 cause a second form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) deregulating RAS-MAPK signaling. Circulation 2017;136:1037-48.
27. Cho BC, Kim JB, Lee JW, et al. Cervicofacial lymphatic malformations: a retrospective review of 40 cases. Arch Plast Surg 2016;43:10-8.
28. Boscolo E, Coma S, Luks VL, et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis 2015;18:151-62.
29. Osborn AJ, Dickie P, Neilson DE, et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum Mol Genet 2015;24:926-38.
30. Park H, Kim JS, Park H, et al. Venous malformations of the head and neck: a retrospective review of 82 cases. Arch Plast Surg 2019;46:23-33.
31. Uebelhoer M, Natynki M, Kangas J, et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 2013;22:3438-48.
32. Couto JA, Vivero MP, Kozakewich HP, et al. A somatic MAP3K3 mutation is associated with verrucous venous malformation. Am J Hum Genet 2015;96:480-6.
33. Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulins, are responsible for glomuvenous malformations (“glomangiomases”). Am J Hum Genet 2002;70:866-74.
34. Soblet J, Kangas J, Natynki M, et al. Blue Rubber Bleb Nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J Invest Dermatol 2017;137:207-16.
35. Cavalcanti DD, Kalani MY, Martirosyan NL, et al. Cerebral cavernous malformations: from genes to proteins to disease. J Neurosurg 2012;116:122-32.
36. Kim JB, Lee JW, Choi KY, et al. Clinical characteristics of arteriovenous malformations of the head and neck. Dermatol Surg 2017;43:526-33.
37. Couto JA, Huang AY, Konczyk DJ, et al. Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet 2017;100:546-54.
38. Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006;140:2155-62.
39. Cole SG, Begbie ME, Wallace GM, et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005;42:577-82.
40. Sung HM, Chung HY, Lee SJ, et al. Clinical experience of the Klippel-Trenaunay syndrome. Arch Plast Surg 2015;42:552-8.
41. Jacob AG, Driscoll DJ, Shaughnessy WJ, et al. Klippel-Trenaunay syndrome: spectrum and management. Mayo Clin Proc 1998;73:28-36.
42. Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 2015;166:1048-54.
43. Mirzaa GM, Riviere JB, Dobyns WB. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCP. Am J Med Genet C Semin Med Genet 2013;163C:122-30.
44. Kurek KC, Luks VL, Ayturk UM, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 2012;90:1108-15.
45. Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011;365:611-9.
46. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011;43:1262-5.